

Amendment Tool

v1.8 30 April 2025

For office use

QC: No

Section 1: Project information

Short project title*:	Perioperative Quality Improvement Programme (PQIP)			
IRAS project ID* (or REC reference if no IRAS project ID is available):	215928			
Sponsor amendment reference number*:	Substantial Amendment SA 10.0			
Sponsor amendment date* (enter as DD/MM/YY):	04 March 2026			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	<p>1. Update to Patient Invitation Letter. This update refreshes the format, logo and wording of the previous letter.</p> <p>2. New site opening - Salisbury District Hospital (Salisbury NHS Foundation Trust). Principal Investigator onsite to be Dr Basant Bhattarai.</p> <p>3. New PI at Tameside General Hospital - Sarah Penkett, ACCP.</p>			
Project type (select):	Specific study			
	<div style="text-align: center;"> <input type="checkbox"/> Research tissue bank <input type="checkbox"/> Research database </div>			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes	No		
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes	No		
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes	No		
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes	No		
Was the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device [^] (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?	Yes	No		
Does the amendment make the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device [^] (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?		Yes	No	
[^] IVD medical devices are tests used on biological samples, such as tissues, blood or urine, to determine the status of a person's health. This may be a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination				
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes	No		
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes	No		
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes	No		
Does the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?: (e.g. the study relies upon section 251 support in England and Wales, or equivalent in Scotland to set aside the common law duty of confidentiality)	Yes	No		
Does the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes	No		
Does the study involve children OR does the amendment introduce this?:	Yes	No		
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes	No		
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes	No		
Lead nation for the study:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	Yes	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes
Which nations had participating non-NHS/HSC organisations prior to this amendment?	Yes	No	No	No

Which nations will have participating non-NHS/HSC organisations after this amendment?	Yes	No	No	No
---	-----	----	----	----

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers. In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Update to PQIP Patient Participation Invitation Letter v4 03.07.2020. This update refreshes the PQIP logo, replaces the word "project" to "programme" where applicable and also rephrases some grammar and contact specifics inline wit site feedback and current practice. New document is PQIP Patient Participation Invitation Letter v5 27.02.2026.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Where are the participating non-NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
				Remove all changes below

Change 2				
Area of change (select)*:	Participating Organisations			
Specific change (select - only available when area of change is selected first)*:	Addition of sites undertaking the same activities as existing sites			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Agreement with new site Salisbury District Hospital Salisbury NHS Foundation Trust Odstock Road Salisbury Wiltshire SP2 8BJ Principal Investigator: Dr Basant Bhattarai b.bhattarai@nhs.net			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Where are the participating non-NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No
				Remove all changes below

Change 3				
Area of change (select)*:	Researchers			
Specific change (select - only available when area of change is selected first)*:	PI - New PI, or temporary arrangements to cover the absence of a PI			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	New PI at Tameside General Hospital - Sarah Penkett ACCP to replace Dr Hafiz Rehman sarah.penkett@tgh.nhs.uk			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	No
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Where are the participating non-NHS/HSC organisations located that will be affected by this change?*	Yes	No	No	No

Add another change

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	pushpsen joshi
Email address*:	pushpsen.joshi1@nhs.net

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies														Category:				
	UK wide:						England and Wales:				Scotland:			Northern Ireland:					
	REC	Competent Authority MHRA – Medicines	Competent Authority MHRA – Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPFS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function		HSC REC	HSC Data Guardians	Prisons	National coordinating function
Change 1:						(Y)				(Y)				(Y)					C
Change 2:						(Y)				(Y)				(Y)					New site
Change 3:						(Y)				(Y)				(Y)					B
Overall reviews for the amendment:																			
Full review:						N				N				N					
Notification only:						Y				Y				Y					
Overall amendment type:	Non-substantial, no study-wide review required																		
Overall Category:	B/C																		